235.74
-26.42 (-10.08%)
| Penutupan Terdahulu | 262.16 |
| Buka | 257.14 |
| Jumlah Dagangan | 1,880,042 |
| Purata Dagangan (3B) | 830,927 |
| Modal Pasaran | 30,511,122,432 |
| Harga / Pendapatan (P/E Ke hadapan) | 909.09 |
| Harga / Jualan (P/S) | 14.52 |
| Harga / Buku (P/B) | 493.41 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 30 Apr 2025 - 5 May 2025 |
| Margin Keuntungan | -12.37% |
| Margin Operasi (TTM) | -17.73% |
| EPS Cair (TTM) | -2.17 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | 34.90% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 4,089.28% |
| Nisbah Semasa (MRQ) | 2.78 |
| Aliran Tunai Operasi (OCF TTM) | -8.31 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | 197.88 M |
| Pulangan Atas Aset (ROA TTM) | -2.74% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Bercampur | Bercampur |
| Biotechnology (Global) | Bercampur | Bercampur | |
| Stok | Alnylam Pharmaceuticals, Inc. | Menaik | Menaik |
AISkor Stockmoo
| Konsensus Penganalisis | 3.0 |
| Aktiviti Orang Dalam | -1.5 |
| Volatiliti Harga | 2.0 |
| Purata Bergerak Teknikal | 2.5 |
| Osilator Teknikal | -3.5 |
| Purata | 0.50 |
|
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia. It also has several clinical programs across various therapeutic areas: genetic medicines; cardio-metabolic diseases; hepatic infectious diseases, and CNS/ocular diseases. Upfront fees from research partnerships have boosted Alnylam's cash levels, and the company stands to see additional milestones and royalties from drugs commercialized under collaboration partnerships. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Mid Core |
| % Dimiliki oleh Orang Dalam | 3.87% |
| % Dimiliki oleh Institusi | 96.39% |
Pemilikan
| Nama | Tarikh | Syer Dipegang |
|---|---|---|
| Regeneron Pharmaceuticals, Inc. | 31 Dec 2024 | 4,444,445 |
| Julat 52 Minggu | ||
| Julat Harga Sasaran | ||
| Tinggi | 500.00 (HC Wainwright & Co., 112.10%) | Beli |
| Median | 330.00 (39.99%) | |
| Rendah | 284.00 (Morgan Stanley, 20.47%) | Pegang |
| Purata | 342.69 (45.37%) | |
| Jumlah | 11 Beli, 2 Pegang | |
| Harga Purata @ Panggilan | 277.49 | |
| Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
|---|---|---|---|---|
| HC Wainwright & Co. | 02 Apr 2025 | 500.00 (112.10%) | Beli | 266.83 |
| 25 Feb 2025 | 500.00 (112.10%) | Beli | 245.20 | |
| Redburn Atlantic | 31 Mar 2025 | 353.00 (49.74%) | Beli | 270.02 |
| Scotiabank | 31 Mar 2025 | 342.00 (45.08%) | Beli | 270.02 |
| 21 Mar 2025 | 338.00 (43.38%) | Beli | 283.34 | |
| Stifel | 31 Mar 2025 | 345.00 (46.35%) | Beli | 270.02 |
| JP Morgan | 24 Mar 2025 | 328.00 (39.14%) | Beli | 290.70 |
| 11 Mar 2025 | 280.00 (18.77%) | Pegang | 238.74 | |
| B of A Securities | 21 Mar 2025 | 325.00 (37.86%) | Beli | 283.34 |
| Canaccord Genuity | 21 Mar 2025 | 390.00 (65.44%) | Beli | 283.34 |
| 18 Feb 2025 | 385.00 (63.32%) | Beli | 250.00 | |
| Chardan Capital | 21 Mar 2025 | 300.00 (27.26%) | Beli | 283.34 |
| 26 Feb 2025 | 300.00 (27.26%) | Beli | 243.86 | |
| Citigroup | 21 Mar 2025 | 351.00 (48.89%) | Beli | 283.34 |
| Needham | 21 Mar 2025 | 320.00 (35.74%) | Beli | 283.34 |
| 26 Feb 2025 | 320.00 (35.74%) | Beli | 243.86 | |
| RBC Capital | 21 Mar 2025 | 330.00 (39.98%) | Beli | 283.34 |
| 26 Feb 2025 | 310.00 (31.50%) | Beli | 243.86 | |
| Wells Fargo | 21 Mar 2025 | 287.00 (21.74%) | Pegang | 283.34 |
| Morgan Stanley | 14 Feb 2025 | 284.00 (20.47%) | Pegang | 256.45 |
| Papar semua | ||||
Tiada data dalam julat masa ini.
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2025 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |